IRIX — IRIDEX Corporation

IRIDEX Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $12.5 million, an 8% year-over-year increase.
• Adjusted EBITDA: Loss of $131,000, an improvement of $1.3 million from Q3 2024.
• Net Loss: $1.6 million ($0.09 per share), compared to a loss of $1.9 million ($0.12 per share) in Q3 2024.
• Gross Profit: $4.0 million with a gross margin of 32.1%, down from 37.3% in Q3 2024, primarily due to a $0.8 million inventory write-down.
• Operating Expenses: $5.4 million, a 12% reduction from $6.2 million in Q3 2024.
• Cash and Cash Equivalents: $5.6 million, down from $6.8 million in Q2 2025.

2. Strategic Updates and Business Highlights:

• Achieved fourth consecutive quarter of revenue growth and reduced operating expenses by 25% year-to-date.
• Strong performance in glaucoma and retina product lines, with notable increases in sales of the Cyclo G6 system and PASCAL system.
• Implementing cost reduction initiatives, including relocating administrative functions to save approximately $165,000 quarterly starting Q1 2026.
• Negotiating with contract manufacturers to reduce cost of goods sold and improve gross margins.

3. Forward Guidance and Outlook:

• Positive cash flow expected in Q4 2025 and positive adjusted EBITDA anticipated for the full year.
• Aiming for cash flow positive operations in 2026, supported by ongoing operational improvements and cost discipline.

4. Bad News, Challenges, or Points of Concern:

• Gross margin decline attributed to a one-time inventory write-down related to transitioning production to contract manufacturers.
• International markets, particularly in Asia, faced volatility due to macroeconomic factors, including tariff disputes and currency fluctuations.
• Regulatory challenges in Europe affecting sales of the PASCAL system, with expectations of pent-up demand once certifications are resolved.

5. Notable Q&A Insights:

• Management emphasized the importance of leveraging technology and customer relationships to drive sales efficiency despite a smaller sales force.
• Concerns were raised about the ongoing tariff disputes impacting sales forecasts, particularly in China and Japan.
• The team reiterated their commitment to maintaining financial prudence and achieving long-term profitability goals.

Overall, IRIDEX demonstrated solid progress in financial performance and strategic initiatives while acknowledging ongoing challenges in international markets and regulatory environments.